REG - Nuformix PLC - Posting of Annual Report and Notice of AGM

NuformixAnnouncement

05/02/2026 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260205:nRSE8839Ra&default-theme=true

RNS Number : 8839R  Nuformix PLC  05 February 2026

5 February 2026

Nuformix plc

("Nuformix" or the "Company")

Posting of Annual Report and Notice of Annual General Meeting ("AGM")

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual Financial Report for the year ended 30 September 2025 (the "Annual
Financial Report 2025") and the 2026 Notice of AGM are today being posted to
its shareholders.

A full pdf version of the Annual Financial Report 2025 together with the
Notice of AGM is available for download from the Investor Information section
on the Company's website: www.nuformix.com (http://www.nuformix.com) .

The Annual General Meeting will be held at the offices of Arch Law, level 2,
Huckletree, 8 Bishopsgate, London, EC2N 4BQ at 9.30 a.m. on 3 March 2026.

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6632

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFIFIAFTIEIIR



            Copyright 2019 Regulatory News Service, all rights reserved